Gilead Sciences | GILD - Trade Creditors


Gilead Sciences reported $645M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
ALKERMES USD 102.36M 5.59M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Coherus Biosciences USD 9.91M 14.98M Dec/2025
Eli Lilly USD 5.03B 350M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
Incyte USD 228.62M 1.41B Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Merck USD 3.86B 541M Mar/2026
Moderna USD 161M 156M Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.71B 219M Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
United Therapeutics USD 498.3M 491.2M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026